(S)-2-(1-Hydroxy-but-2-ylamino)-6-[4-(5-pyrimidinyl)phenylamino]-9-iso-propylpurine

ID: ALA2295953

PubChem CID: 76331200

Max Phase: Preclinical

Molecular Formula: C22H26N8O

Molecular Weight: 418.51

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCC[C@H](O)Nc1nc(Nc2ccc(-c3cncnc3)cc2)c2ncn(C(C)C)c2n1

Standard InChI:  InChI=1S/C22H26N8O/c1-4-5-18(31)27-22-28-20(19-21(29-22)30(13-25-19)14(2)3)26-17-8-6-15(7-9-17)16-10-23-12-24-11-16/h6-14,18,31H,4-5H2,1-3H3,(H2,26,27,28,29)/t18-/m0/s1

Standard InChI Key:  LQYHWFFRRIMAPW-SFHVURJKSA-N

Molfile:  

     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
    6.7110  -18.8924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9695  -16.4250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.0920  -14.3670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1370  -18.0703    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.0951  -15.1888    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3963  -20.0959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6747  -15.1926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2904  -18.8913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8198  -18.4795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2609  -16.8389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5514  -16.4262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6698  -14.3750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0416  -20.5337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3378  -17.8112    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.5563  -18.8890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9675  -15.6032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7118  -18.0715    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.2509  -15.1972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8466  -19.3064    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.8447  -17.6616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3871  -15.5995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5452  -15.6094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8423  -16.8409    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.3749  -13.9579    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.5934  -19.9246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5560  -18.0667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1359  -18.8935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5798  -19.3032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0004  -19.3044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4211  -19.3055    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.3382  -19.1442    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
 20  4  1  0
  8 28  1  0
  1 17  1  6
 31 25  1  0
 25 13  1  0
 24 12  2  0
 15 31  1  0
 29  8  1  0
 22 11  1  0
 31  9  1  0
 12  7  1  0
 18 22  2  0
 14 26  1  0
 20 23  1  0
 23 11  1  0
 26 15  1  0
 10  2  1  0
 30  1  1  0
 25  6  1  0
  9 14  2  0
  2 16  2  0
 27 19  1  0
 27 30  1  0
  5  3  2  0
 11 10  2  0
 16  7  1  0
  1 29  1  0
  7 21  2  0
 26 20  2  0
 16 18  1  0
  3 24  1  0
  4 27  2  0
 21  5  1  0
 19 15  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA2295953

   (1S)-1-[[9-propan-2-yl-6-(4-pyrimidin-5-ylanilino)purin-2-yl]amino]butan-1-ol

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 418.51

Molecular Weight (Monoisotopic): 418.2230

AlogP: 4.14

#Rotatable Bonds: 8

Polar Surface Area: 113.67

Molecular Species: NEUTRAL

HBA: 9

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.51

CX Basic pKa: 3.64

CX LogP: 3.34

CX LogD: 3.34

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.37

Np Likeness Score: -0.84

References

1. Demange L, Lozach O, Ferandin Y, Hoang NT, Meijer L, Galons H.  (2013)  Synthesis and evaluation of new potent inhibitors of CK1 and CDK5, two kinases involved in Alzheimers disease,  22  (7): [10.1007/s00044-012-0334-1]

2. Gray, N S NS and 12 more authors.  1998-07-24  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.  [PMID:9677190]

3. Kubo, A A and 9 more authors.  1999-12  The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.  [PMID:10632371]

4. Lane, M E ME and 9 more authors.  2001-08-15  A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.  [PMID:11507069]

5. Bramson, H N HN and 20 more authors.  2001-12-06  Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.  [PMID:11728181]

6. Mettey, Yvette Y and 9 more authors.  2003-01-16  Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.  [PMID:12519061]

7. Wang, Yihan Y and 18 more authors.  2003-09-15  Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.  [PMID:12941335]

8. Sayle, Kerry L KL and 16 more authors.  2003-09-15  Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.  [PMID:12941338]

9. Tavares, Francis X FX and 7 more authors.  2004-09-09  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.  [PMID:15341487]

10. Feldman, Richard I RI and 17 more authors.  2005-05-20  Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.  [PMID:15772071]

11. Lin, Ronghui R and 11 more authors.  2005-06-30  1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.  [PMID:15974571]

12. Pennati, Marzia M and 12 more authors.  2005-09  Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.  [PMID:16170024]

13. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N.  2006-03-24  Selectivity and potency of cyclin-dependent kinase inhibitors.  [PMID:16584130]

14. DePinto, Wanda W and 19 more authors.  2006-11  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.  [PMID:17121911]

15. Wyatt, Paul G PG and 22 more authors.  2008-08-28  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.  [PMID:18656911]

16. Jones, Clifford D CD and 18 more authors.  2008-12-15  The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.  [PMID:18996007]

17. Squires, Matthew S MS and 7 more authors.  2009-02  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.  [PMID:19174555]

18. Gaisina, Irina N IN and 10 more authors.  2009-04-09  From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.  [PMID:19338355]

19. Hall, Matthew D and 8 more authors.  2009-05-28  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.  [PMID:19397322]

20. Ali, Simak S and 16 more authors.  2009-08-01  The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.  [PMID:19638587]

21. Zarrinkar, Patrick P PP and 15 more authors.  2009-10-01  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).  [PMID:19654408]

22. Aronov, Alex M AM and 20 more authors.  2009-10-22  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.  [PMID:19827834]

23. Angiolini, Mauro M and 7 more authors.  2010-07-15  Structure-based optimization of potent PDK1 inhibitors.  [PMID:20621725]

24. Laha, Joydev K JK and 7 more authors.  2011-04-01  Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.  [PMID:21353545]

25. William, Anthony D AD and 16 more authors.  2012-03-22  Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.  [PMID:22339472]

26. Hole, Alison J and 9 more authors.  2013-02-14  Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.  [PMID:23252711]

27. Cirstea, D D and 15 more authors.  2013-12  Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.  [PMID:23807770]

28. Martin, Mathew P MP, Olesen, Sanne H SH, Georg, Gunda I GI and Schönbrunn, Ernst E.  2013-11-15  Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.  [PMID:24007471]

29. Reddy, M V Ramana MV and 12 more authors.  2014-02-13  Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).  [PMID:24417566]

30. Blake, James F JF and 24 more authors.  2014-06-15  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.  [PMID:24813737]

31. Hanan, Emily J EJ and 24 more authors.  2014-12-11  Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.  [PMID:25383627]

32. Paiva, Cody C and 8 more authors.  2015  Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.  [PMID:26606677]

33. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC.  2016-05  Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.  [PMID:26826116]

34. Sonawane, Yogesh A and 5 more authors.  2016-10-13  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.  [PMID:27171036]

35. Coxon, Christopher R and 20 more authors.  2017-03-09  Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.  [PMID:28005359]

36. Klaeger, Susan S and 47 more authors.  2017-12-01  The target landscape of clinical kinase drugs.  [PMID:29191878]

37. Patel, Hetal H and 15 more authors.  2018-06  ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.  [PMID:29545334]

38. Wang, Yiting Y and 6 more authors.  2018-07-23  Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.  [PMID:29853338]

39. Zhi, Yanle Y and 9 more authors.  2018-07-15  Discovery of the selective and efficacious inhibitors of FLT3 mutations.  [PMID:29894944]

40. Sánchez-Martínez, Concepción; Lallena, María José; Sanfeliciano, Sonia Gutiérrez and de Dios, Alfonso.  2019-10-15  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).  [PMID:31477350]

41. Teng, Yuou and 10 more authors.  2019-12-01  Recent advances in the development of cyclin-dependent kinase 7 inhibitors.  [PMID:31514062]

42. Tear, Westley F and 16 more authors.  2020-01-23  Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis.  [PMID:31846577]

43. Wu, Tizhi and 6 more authors.  2020-11-25  Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.  [PMID:32866383]

Source

Source(1):

• Scientific Literature